Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04614064
Other study ID # 20SM6236
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 16, 2021
Est. completion date July 20, 2023

Study information

Verified date July 2023
Source Imperial College London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An average of 4.8 million journeys are made on the London Underground every day and as the 'Tube' has elevated airborne particulate matter concentrations compared to ambient air, this raises concern about the potential health impact of this environment. This study explores the health effects of particulate matter from the London Underground on patients with COPD and healthy volunteers. Patients with COPD and healthy participants will be invited to undertake a set 90 min journey on the London Underground, and on a separate occasion (3-8 weeks apart), a 90 min journey on the London Overground (as a proxy for a clean air London area while maintaining other aspects of a train journey). A series of clinical, physiological and inflammatory data will be collected before, during and after (at different time points) each of the sessions in order to compare their response in relation to exposure and/or to disease status.


Recruitment information / eligibility

Status Completed
Enrollment 83
Est. completion date July 20, 2023
Est. primary completion date July 20, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 90 Years
Eligibility Inclusion Criteria for both groups: - Give informed consent - London resident For participants with COPD: - GOLD stage 2 COPD (FEV1/FVC<70%; 50%>FEV1<80% predicted), GOLD stage 3 COPD (FEV1/FVC<70%; 30%>FEV1<50%) and GOLD stage 4 (FEV1/FVC<70%;FEV1<30%) - No history of ischaemic heart disease For healthy volunteers: - No history of ischaemic heart disease. - Normal lung function with no evidence of airflow obstruction. Exclusion Criteria for both participants with COPD and healthy volunteers: - Those with unstable ischaemic heart disease or COPD. - Current smokers and those who are ex-smokers of <12 months duration. - Those who work in the London Underground or are occupationally exposed to - - high levels of vehicle traffic exposure on a frequent basis. - Those who cannot walk for 30 mins. - Involvement in another research study - Those unable to give consent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exposure to London Underground ambient particulate matter
Exposure to particulate matter on the London Underground
Exposure to London air ambient particulate matter
Exposure to ambient particulate matter on the London Overground (as a proxy as a proxy for a clean air London area while maintaining other aspects of a train journey)

Locations

Country Name City State
United Kingdom Imperial Clinical Research Facility London

Sponsors (2)

Lead Sponsor Collaborator
Imperial College London Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Sinharay R, Gong J, Barratt B, Ohman-Strickland P, Ernst S, Kelly FJ, Zhang JJ, Collins P, Cullinan P, Chung KF. Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, crossover study. Lancet. 2018 Jan 27;391(10118):339-349. doi: 10.1016/S0140-6736(17)32643-0. Epub 2017 Dec 5. Erratum In: Lancet. 2018 Jan 27;391(10118):308. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The difference (London Underground vs control exposure) in post exposure pulse wave velocity in healthy vs COPD participants. Measurement of arterial stiffness -2 hours, +2 hours, +5 hours, +6 hours, +24 hours
Secondary Other clinical responses on the London Underground vs control exposure Symptom questionnaire -2 hours, 0 hours, +45 minutes +90 minutes, +4 hours, +5 hours, +6 hours, +24 hours
Secondary Other clinical responses on the London Underground vs control exposure Spirometry (FEV1) -2 hours, 0 hours, +45 minutes, +90 minutes, +2 hours, +4 hours, +6 hours, +24 hours
Secondary Other clinical responses on the London Underground vs control exposure Spirometry (FVC) -2 hours, 0 hours, +45 minutes, +90 minutes, +2 hours, +4 hours, +6 hours, +24 hours
Secondary Other clinical responses on the London Underground vs control exposure Spirometry (FEF 25-75) -2 hours, 0 hours, +45 minutes, +90 minutes, +2 hours, +4 hours, +6 hours, +24 hours
Secondary Other clinical responses on the London Underground vs control exposure Single breath transfer factor for carbon monoxide (TLCO) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Blood sample (IL8) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Blood sample (High sensitivity CRP) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Blood sample (FBC) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Blood sample (TNFa) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Blood sample (vWf antigen) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Blood sample (Thrombin generation (systemic inflammatory response)) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Blood sample (8-isoprostanes (ELISA)) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Blood sample (Blood malondialdehyde (lipid peroxidation)) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Blood sample (Oxidation Reduction Potential (oxidative stress)) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (IL-8) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (IL-6) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (IL-33) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (Myeloperoxidase) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (Neutrophil lipocalin-2) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (Tryptases) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (Complement) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (vWf antigen) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (Thrombin generation) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasosorption (D-dimer activation) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Nasal curettage (mRNA levels to elucidate molecular mechanisms that may explain the toxic effects of particulate matter) -2 hours, +7 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Urine (8-isoprostane) -2 hours, +24 hours
Secondary Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure Urine (8-hydroxy 2-deoxyguanosine) -2 hours, +24 hours
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy